News coverage about Harvard Bioscience (NASDAQ:HBIO) has been trending positive on Tuesday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Harvard Bioscience earned a media sentiment score of 0.32 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 44.7918770810558 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern Sentiment’s analysis:

HBIO has been the topic of several recent analyst reports. Janney Montgomery Scott raised their target price on shares of Harvard Bioscience from $5.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Benchmark raised their target price on shares of Harvard Bioscience from $6.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, January 23rd. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $6.92.

Harvard Bioscience (NASDAQ:HBIO) opened at $4.50 on Tuesday. The company has a quick ratio of 1.87, a current ratio of 3.40 and a debt-to-equity ratio of 0.13. Harvard Bioscience has a 1-year low of $2.25 and a 1-year high of $4.85. The company has a market cap of $158.71, a PE ratio of -50.00 and a beta of 1.30.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/02/13/harvard-bioscience-hbio-earns-media-sentiment-rating-of-0-32.html.

About Harvard Bioscience

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Insider Buying and Selling by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.